Lapatinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3623 publications

Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.

Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.

Journal: Future science OA

Published: April 04, 2026

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: March 06, 2026

Identification and functional exploration of hub genes related to energy metabolism in acute myeloid leukemia.

Identification and functional exploration of hub genes related to energy metabolism in acute myeloid leukemia.

Journal: Hematology (Amsterdam, Netherlands)

Published: March 02, 2026

The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity.

The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: February 16, 2026

Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines.

Actions of Midostaurin as Cation Channel and Tyrosine Kinase Inhibitor in Diffuse Intrinsic Pontine Glioma Cell Lines.

Journal: Cancers

Published: February 13, 2026

Repurposing Lapatinib and Tucatinib as Dual Inhibitors of Bcl-2 and TYMS in Breast Cancer: Insights from Transcriptomic, Computational and Cellular Assays.

Repurposing Lapatinib and Tucatinib as Dual Inhibitors of Bcl-2 and TYMS in Breast Cancer: Insights from Transcriptomic, Computational and Cellular Assays.

Journal: Applied biochemistry and biotechnology

Published: February 04, 2026

In Silico Molecular Docking and Pharmacokinetic Evaluation of Cannabinoid Derivatives as Multi-Target Inhibitors for EGFR, VEGFR-1, and VEGFR-2 Proteins.

In Silico Molecular Docking and Pharmacokinetic Evaluation of Cannabinoid Derivatives as Multi-Target Inhibitors for EGFR, VEGFR-1, and VEGFR-2 Proteins.

Journal: Current issues in molecular biology

Published: January 21, 2026

Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

Journal: Journal of pharmaceutical policy and practice

Published: January 16, 2026

A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.

A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.

Journal: Cancers

Published: January 13, 2026

Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.

Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.

Journal: American journal of men's health

Published: January 07, 2026

Structure-based drug repurposing reveals ponatinib and lapatinib as stable inhibitors of Aurora kinase B: Mechanistic insights from high-resolution molecular dynamics and free-energy analyses.

Structure-based drug repurposing reveals ponatinib and lapatinib as stable inhibitors of Aurora kinase B: Mechanistic insights from high-resolution molecular dynamics and free-energy analyses.

Journal: Computational biology and chemistry

Published: December 30, 2025

Cost Variation and Affordability of Oral Targeted Cancer Therapy in India: Comparison of Branded and Janaushadhi Products.

Cost Variation and Affordability of Oral Targeted Cancer Therapy in India: Comparison of Branded and Janaushadhi Products.

Journal: Cureus

Published: December 27, 2025

Showing 1-12 of 3,623

Last Updated: 04/28/2026